滤泡性淋巴瘤的预后分层和治疗进展

Prognostic stratification and treatment progress of follicular lymphoma

滤泡性淋巴瘤(Follicular lymphoma,FL)是非霍奇金淋巴瘤(Non-Hodgkin′s lymphoma,NHL)中发病率仅次于弥漫大B细胞淋巴瘤的常见B细胞淋巴瘤。FL属于惰性淋巴瘤,尽管该疾病进展缓慢但并不能治愈,且由于复发及进展,严重影响着患者的生存。近年来,针对FL的“无化疗”方案疗效确切且毒性较低,新型免疫治疗和靶向药物也显示较好疗效,受到研究者的广泛关注。为进一步加深临床医生对FL治疗新进展的认识,本文对FL的分层及治疗进展进行综述。

Follicular lymphoma(FL)is a common B-cell lymphoma with an incidence of non-Hodgkin′s lymphoma(NHL)that is second only to diffuse large B lymphoma.FL is an indolent lymphoma.Although the disease progresses slowly,it cannot be cured,and due to recurrence and progression,it seriously affects the survival of patients.In recent years,the“no-chemotherapy”regimen for FL has exact curative effect and low toxicity;the new immunotherapy and targeted drugs also show good curative effect,which has attracted widespread attention from researchers.In order to further deepen the clinician′s understanding of the new progress of FL treatment,this article reviews the stratification and treatment progress of FL.